Oliver Sol

Chief Tech/Sci/R&D Officer presso AC IMMUNE SA

58 anni

Health Technology

Consumer Services

Profilo

Oliver Sol is currently working as the VP & Head-Clinical Development at AC Immune SA. Previously, he worked as the Clinical Director at Exonhit and as the Director-Medical & Regulatory Affairs at Eurobio-Scientific SA. Dr. Sol holds a doctorate degree from Université de Paris XI Paris Sud.

Posizioni attive di Oliver Sol

Società	Posizione	Inizio
AC IMMUNE SA	Chief Tech/Sci/R&D Officer	-

Tutte le posizioni attive di Oliver Sol

Precedenti posizioni note di Oliver Sol

Società	Posizione	Fine
EUROBIO SCIENTIFIC	Chief Tech/Sci/R&D Officer	-
Exonhit Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France.	Chief Tech/Sci/R&D Officer	-

Vedi nel dettaglio l'esperienza di Oliver Sol

Formazione di Oliver Sol

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Oliver Sol

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
AC IMMUNE SA	Health Technology
EUROBIO SCIENTIFIC	Health Technology

Aziende private	2
Exonhit Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France.	Health Technology
Université de Paris XI Paris Sud	Consumer Services